Tomaralimab

Tomaralimab Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Products Intro: Product Name:Tomaralimab
CAS:1449294-76-1
Purity:SDS-PAGE:95% SEC-HPLC:99.99% Package:1mg;222USD|5mg;553USD|10mg;796USD
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 021-61312847; 18021002903
Email: 3008007409@qq.com
Products Intro: Product Name:Tomaralimab (anti-TLR2)
CAS:1449294-76-1
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13746
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Tomaralimab
CAS:1449294-76-1
Purity:95% Package:100ug;500ug;1mg
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Products Intro: Product Name:Tomaralimab
CAS:1449294-76-1
Purity:95% Package:1mg;1g;100g
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Tomaralimab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg

Tomaralimab manufacturers

  • Tomaralimab
  • Tomaralimab pictures
  • $157.00 / 1mg
  • 2026-03-13
  • CAS:1449294-76-1
  • Min. Order:
  • Purity: 100% (SEC-HPLC)
  • Supply Ability: 10g
Tomaralimab Basic information
Product Name:Tomaralimab
Synonyms:Tomaralimab;Research Grade Tomaralimab (DHA95501);OPN-305;Research Grade Tomaralimab;Tomaralimab (anti-TLR2)
CAS:1449294-76-1
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Tomaralimab Structure
Tomaralimab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Tomaralimab Usage And Synthesis
UsesTomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS)[1].
References[1] GuillermoGarcia-ManeroMD, et al. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 798.
Tomaralimab Preparation Products And Raw materials
Tag:Tomaralimab(1449294-76-1) Related Product Information
Remtolumab Samrotamab Iodine (131I) Apamistamab Disitamab Prezalumab Tafolecimab Praluzatamab Placulumab Imalumab Gimsilumab